Oral Glucose Tolerance Test (OGTT): Medication-Driven Changes, Normal Ranges, and What Your Results Mean

What the OGTT Measures and Why It Matters for Women

The OGTT captures the full arc of your glucose response to a standardized sugar challenge: where you start (fasting), how high you spike, and how completely you recover. A fasting glucose alone can miss significant insulin resistance because some women clear fasting glucose normally but mount a prolonged, exaggerated post-load response. That pattern is particularly common in women with polycystic ovary syndrome, in perimenopause, and in postpartum women recovering from gestational diabetes mellitus (GDM).

The American Diabetes Association (ADA) classifies the two-hour post-load value as follows:

| Result | 2-Hour Plasma Glucose | |---|---| | Normal | <140 mg/dL | | Prediabetes (impaired glucose tolerance) | 140-199 mg/dL | | Diabetes | ≥200 mg/dL |

Longevity-medicine and functional-medicine clinicians frequently apply a tighter optimal target of <120 mg/dL at two hours. That threshold has no formal guideline endorsement yet, but it is grounded in data from the Whitehall II cohort showing that post-load glucose values between 120 and 140 mg/dL already carry a graded increase in cardiovascular risk. For a woman in her reproductive years who plans to conceive, getting well inside the normal range before pregnancy substantially reduces GDM risk.

Why Women Need a Different Frame

Estrogen improves insulin sensitivity; progesterone blunts it. This means your OGTT result is not static across your cycle or your life. A test done in the luteal phase (days 15-28) may read several mg/dL higher than the same test done in the follicular phase, though this fluctuation is rarely large enough to move you across a diagnostic threshold. The more clinically meaningful hormonal effects come from pregnancy, from the estrogen withdrawal of menopause, and from exogenous hormones.

Women also carry a specific post-GDM risk that men simply do not face. Roughly 50% of women diagnosed with GDM develop type 2 diabetes within five to ten years. Annual or biennial OGTT monitoring in this group is recommended by ACOG Practice Bulletin 190 and is more sensitive than fasting glucose alone for catching early deterioration.

The Medication-Driven Changes That Distort Your OGTT

This is where interpretation gets genuinely difficult. A single medication can shift a two-hour OGTT value by 20-50 mg/dL, moving a woman across a diagnostic threshold without any real change in her metabolic health. Your ordering clinician should document every medication you are taking before the test, and you should not discontinue any prescription drug without guidance.

Medications That Raise OGTT Values

Glucocorticoids are the most clinically significant. Prednisone, dexamethasone, and inhaled budesonide at high doses all increase hepatic glucose output and impair peripheral glucose uptake. A 2013 review in Diabetes Care documented that steroid-induced hyperglycemia peaks four to eight hours after the morning dose, meaning a standard two-hour OGTT underestimates the degree of steroid dysglycemia. Women with autoimmune conditions (lupus, rheumatoid arthritis, inflammatory bowel disease) who require ongoing glucocorticoids need this caveat explicitly noted in their OGTT interpretation.

Thiazide diuretics (hydrochlorothiazide, chlorthalidone) worsen glucose tolerance through hypokalemia-mediated reduction of insulin secretion. The ALLHAT trial found that chlorthalidone increased the four-year incidence of new-onset diabetes compared to amlodipine or lisinopril. If you are on a thiazide for hypertension, a borderline OGTT result warrants a conversation about whether potassium replacement or a drug class switch changes the picture.

Atypical antipsychotics (olanzapine, clozapine, quetiapine) cause insulin resistance independent of weight gain. This matters specifically for women because second-generation antipsychotics are used in reproductive-age women for bipolar disorder, schizophrenia, and increasingly off-label for treatment-resistant depression. A meta-analysis in JAMA Psychiatry found that olanzapine raised fasting glucose by a mean of 9.8 mg/dL and two-hour post-load glucose proportionally more.

Progestins used in hormonal contraception deserve specific attention for women. High-dose synthetic progestins (levonorgestrel, norethindrone acetate at contraceptive doses) have measurable glucose-raising effects. A Cochrane review of hormonal contraception and metabolic effects found small but detectable rises in insulin resistance with combined oral contraceptives containing levonorgestrel. Progesterone-only pills using drospirenone or desogestrel show less effect. If you are having a baseline OGTT for PCOS evaluation or pre-conception planning, the type of progestin you are currently using belongs in the clinical note.

Beta-blockers (atenolol, metoprolol) blunt the catecholamine-mediated symptoms of hypoglycemia and independently impair insulin secretion. They tend to raise post-load glucose values modestly while masking the sweating and tremor that would otherwise alert a woman to a hypoglycemic dip during the test.

Other notable glucose-raising agents include:

• Niacin (nicotinic acid) at lipid-lowering doses
• Tacrolimus and cyclosporine (post-transplant immunosuppressants)
• Fluoroquinolone antibiotics (ciprofloxacin, levofloxacin) in susceptible individuals
• Megestrol acetate, used for appetite stimulation and in some gynecologic cancers

Medications That Lower OGTT Values

Metformin is the clearest case. It suppresses hepatic glucose output and improves insulin sensitivity enough to reduce the two-hour OGTT value by 30-60 mg/dL in women with prediabetes. The Diabetes Prevention Program (DPP) trial showed metformin reduced progression from prediabetes to diabetes by 31% in the overall cohort, with particularly strong effects in women aged 25-44. If you are on metformin and your OGTT comes back normal, that result does not mean your underlying metabolic risk has resolved. It means metformin is doing its job.

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) produce pronounced reductions in post-load glucose through a combination of delayed gastric emptying, enhanced glucose-dependent insulin secretion, and suppressed glucagon. Women on semaglutide for weight management who undergo an OGTT while on the drug will likely show a two-hour value 40-80 mg/dL lower than their off-drug baseline. This is an area where the evidence in women specifically is thin. Most published pharmacokinetic data comes from trials where women were included but subgroup data by sex were not always reported separately.

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) lower glucose by increasing urinary glucose excretion. They will artificially reduce plasma glucose values across the entire OGTT curve. A woman on an SGLT2 inhibitor who is undergoing OGTT for GDM screening should not be tested while on the drug. ACOG and the Society for Maternal-Fetal Medicine recommend stopping SGLT2 inhibitors before pregnancy and during pregnancy due to fetal risk (see the pregnancy and lactation section below).

Salicylates at high doses (aspirin 3-5 g/day, as used historically in rheumatologic conditions) improve insulin sensitivity through NF-kB inhibition. Low-dose aspirin (81-100 mg/day) does not produce a measurable OGTT effect.

Berberine, a botanical compound increasingly used for PCOS and metabolic support, has glucose-lowering effects comparable in some studies to low-dose metformin. A 2008 randomized trial found berberine reduced two-hour OGTT values by approximately 35 mg/dL in participants with type 2 diabetes. Women using berberine as a supplement should disclose this before OGTT testing.

OGTT Across Female Life Stages

Reproductive Years and PCOS

Women with PCOS have a two-to-four times higher prevalence of impaired glucose tolerance than age-matched controls, even at normal BMI. The Androgen Excess and PCOS Society recommends an OGTT (not just fasting glucose) as the preferred screening tool in this population because fasting glucose misses up to 50% of cases of impaired glucose tolerance in PCOS. If you have PCOS, a normal fasting glucose is not sufficient reassurance. You need the full two-hour challenge.

The menstrual cycle phase at the time of testing can introduce variability of roughly 5-10 mg/dL in the two-hour value. This is not large enough to change diagnosis in most cases, but for borderline results it is worth noting in the chart and repeating the test in the early follicular phase if there is uncertainty.

Trying to Conceive

Pre-conception OGTT matters because insulin resistance impairs ovulation, increases miscarriage risk, and raises the probability of developing GDM. Women with a history of GDM, PCOS, or BMI ≥30 kg/m² should have an OGTT before conception. Getting the two-hour value below 120 mg/dL before pregnancy is a reasonable functional target that gives the best buffer against crossing the GDM threshold once pregnancy-related insulin resistance intensifies in the second trimester.

Pregnancy and Gestational Diabetes

Pregnancy is the most clinically consequential context for OGTT in women. Insulin resistance rises physiologically in the second and third trimesters under the influence of placental lactogen, progesterone, and cortisol. ACOG Practice Bulletin 190 recommends universal GDM screening between 24 and 28 weeks of gestation.

Two diagnostic protocols exist in the United States:

One-step protocol (IADPSG/ADA-endorsed, 75 g):

| Threshold (meets or exceeds) | Value | |---|---| | Fasting | 92 mg/dL | | 1-hour | 180 mg/dL | | 2-hour | 153 mg/dL |

GDM is diagnosed if any single value meets or exceeds threshold.

Two-step protocol (ACOG-preferred, 50 g screen then 100 g diagnostic):

The 50 g, one-hour glucose challenge test (GCT) is given without fasting. A value ≥130 or ≥140 mg/dL (threshold varies by institution) triggers the full 100 g, three-hour OGTT. GDM is diagnosed when two or more of the following Carpenter-Coustan values are met or exceeded: fasting 95, one-hour 180, two-hour 155, three-hour 140 mg/dL.

ACOG continues to endorse the two-step approach as it produces fewer false positives and has the most outcome data in U.S. Populations, though the one-step protocol identifies more women with milder dysglycemia.

Medications in pregnancy that confound the OGTT:

Progesterone supplementation used in early pregnancy (vaginal progesterone, oral micronized progesterone) raises insulin resistance slightly, an effect that is usually clinically trivial but worth noting for women on high-dose progesterone for IVF pregnancies. Betamethasone given for fetal lung maturity causes a sharp, transient spike in maternal glucose for 48-72 hours and will completely invalidate any OGTT done in that window. SGLT2 inhibitors carry an FDA warning against use in the second and third trimester due to fetal renal toxicity, and should be stopped before conception or as soon as pregnancy is confirmed.

Postpartum

Every woman diagnosed with GDM should have a 75 g OGTT at 4-12 weeks postpartum, as recommended by ACOG. This test is distinct from the routine hemoglobin A1c because A1c is less sensitive in the early postpartum period due to the increased red blood cell turnover of pregnancy. Breastfeeding improves insulin sensitivity, so an OGTT done while actively breastfeeding may read slightly lower than one done after weaning. That is not a reason to avoid the test; it is a reason to document the feeding status at the time of testing.

Perimenopause

Estrogen withdrawal during perimenopause reduces insulin sensitivity at the tissue level. Visceral fat accumulates even without significant weight gain, and post-load glucose values tend to rise. The WHI observational data and smaller mechanistic studies suggest that menopausal hormone therapy (MHT) with transdermal estradiol improves insulin sensitivity and may partially reverse the perimenopausal rise in post-load glucose. Oral estrogen has a less favorable effect because first-pass hepatic metabolism raises triglycerides. If you are perimenopausal and your OGTT has deteriorated compared to a prior result, discussing MHT with your clinician is a legitimate part of the metabolic conversation.

Postmenopause

Glucose tolerance continues to worsen with aging. Post-load glucose is a stronger predictor of cardiovascular mortality in women than in men at equivalent glucose levels, based on data from the DECODE study. This sex difference in post-load glucose cardiovascular risk is one reason the OGTT is particularly worth doing in postmenopausal women who have borderline fasting glucose or A1c.

Optimal OGTT Targets: What Longevity Medicine Adds

Standard guidelines draw the line at <140 mg/dL for normal and ≥200 mg/dL for diabetes. Longevity-medicine and precision-metabolic-health clinicians use a layered target system that gives women more granular information about where they sit on the risk curve before they cross a diagnostic threshold.

A practical three-zone framework for non-pregnant women:

| Zone | 2-Hour Post-Load Glucose | Clinical Interpretation | |---|---|---| | Optimal | <120 mg/dL | Lowest cardiovascular and diabetes risk; aim here pre-conception | | Acceptable / monitor | 120-139 mg/dL | Elevated trajectory; lifestyle and medication review warranted | | Impaired glucose tolerance | 140-199 mg/dL | Prediabetes by ADA criteria; formal intervention indicated | | Diabetes | ≥200 mg/dL | Diagnostic; treatment required |

This framework is not endorsed by ADA or ACOG as a formal diagnostic scheme. It reflects the risk-gradient data from the Whitehall II cohort and similar prospective studies. WomanRx uses it as an interpretive aid, not as a replacement for guideline-based diagnosis. "Normal" and "optimal" are not the same target. A woman in her late 30s with PCOS who scores 138 mg/dL is technically normal by ADA criteria and at substantially elevated long-term risk.

Who Should Have an OGTT (and Who Should Not Skip It)

An OGTT is more sensitive than fasting glucose or A1c alone for detecting impaired glucose tolerance in women. The following groups should consider it specifically:

• Women with PCOS at any BMI
• Women with a prior GDM diagnosis (annually or biennially)
• Women with BMI ≥30 kg/m², a family history of type 2 diabetes, or acanthosis nigricans
• Perimenopausal women with new-onset central adiposity
• Women on long-term glucocorticoids, antipsychotics, or high-dose progestins
• Anyone with an A1c in the 5.5-6.4% range who wants a more complete picture
• Pre-conception workup in women with insulin resistance signs

The OGTT is not appropriate on the same day as a steroid injection or within 48 hours of betamethasone administration. It should be deferred if you have active illness, as acute illness raises cortisol and will falsely raise results. The test also requires you to have eaten at least 150 g of carbohydrates per day for three days before testing. A low-carbohydrate diet in the days before the test will cause falsely elevated post-load values because the pancreatic beta cells have downregulated insulin secretion.

How to Prepare for Your OGTT: A Practical Women's Checklist

Preparation is where medication documentation is most critical. At least one week before your test, give your clinician a complete medication and supplement list including:

• All prescription medications, including patch, ring, or injectable contraceptives
• Over-the-counter supplements (berberine, inositol, chromium, alpha-lipoic acid all affect glucose)
• Any recent course of antibiotics or steroids

On the day of the test, fast for 8-14 hours. Water is allowed. Do not exercise intensely the morning of the test as acute exercise lowers blood glucose and will underestimate your true response. Sit quietly during the two-hour window. Smoking, even a single cigarette, raises glucose acutely and will invalidate the result.

The ADA Standards of Medical Care specify that a positive OGTT should be confirmed on a separate day with a repeat test before a diagnosis of diabetes is made, unless the result is unambiguously high (≥200 mg/dL with symptoms) or accompanied by a confirmatory A1c ≥6.5%.

Pregnancy and Lactation Safety of Glucose-Modifying Medications

This section addresses the medications most commonly used to treat abnormal OGTT findings.

Metformin in pregnancy: Metformin crosses the placenta. Fetal exposure is approximately 50% of maternal plasma concentration. It is used off-label for GDM in many countries. The MiG trial (Rowan et al., NEJM 2008) showed non-inferiority to insulin for GDM glycemic control. Neonatal outcomes were similar, but offspring showed slightly higher subcutaneous fat at age two in some follow-up studies, meaning long-term pediatric safety remains an open question. Metformin is classified as relatively safe in lactation; milk transfer is approximately 0.3% of the maternal weight-adjusted dose based on pharmacokinetic studies. ACOG and most international guidelines consider metformin a reasonable alternative to insulin for GDM when insulin is declined or unavailable.

GLP-1 receptor agonists in pregnancy: Semaglutide, liraglutide, and tirzepatide are contraindicated in pregnancy. Rodent teratogenicity data exist, and there is insufficient human safety data. Women of reproductive age on semaglutide or tirzepatide should use reliable contraception. The FDA label for semaglutide (Ozempic/Wegovy) recommends stopping the drug at least two months before a planned conception due to its long half-life and the absence of human pregnancy safety data. Lactation: no human data exist; breastfeeding is not recommended while on GLP-1 agonists.

SGLT2 inhibitors in pregnancy: Contraindicated in the second and third trimester. FDA issued a Drug Safety Communication in 2021 warning of fetal kidney toxicity. Stop before conception or immediately upon confirmed pregnancy. Do not use during lactation; animal data suggest renal harm in neonates during a critical developmental window.

Inositol (myo-inositol and D-chiro-inositol): Used widely for PCOS-related insulin resistance. Data from a 2020 systematic review in Fertility and Sterility suggest myo-inositol is safe in pregnancy and may reduce GDM incidence in high-risk women. It is not considered a drug, and no formal pregnancy category exists, but the safety profile appears favorable.

Evidence Gaps: Where the Data on Women Is Thin

Women have been underrepresented in the metabolic trials that establish OGTT interpretation thresholds. The original DECODE study and Whitehall II cohort included women, but sex-disaggregated pharmacokinetic data for GLP-1 agonists on OGTT outcomes are not routinely published. Body composition differences (women carry a higher fat-to-lean mass ratio) mean drug distribution and glucose-lowering effect may differ from male-predominant trial data, but this has not been formally studied for OGTT specifically. The longevity-medicine optimal target of <120 mg/dL is extrapolated from cardiovascular risk data, not from randomized trials showing that treating a value between 120 and 140 mg/dL improves outcomes in non-pregnant women. That trial does not exist yet.